Ohr Pharmaceutical Inc (OHRP) 7.79 $OHRP
Retinal Vein Occlusion - Pipeline Review, H2 2014 - 8 Companies & 10 Drug Profiles
M2 - 1 hr 42 mins ago
Research and Markets (http://www.researchandmarkets.com/research/3bmznr/retinal_vein) has announced the addition of the "Retinal Vein Occlusion - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Retinal Vein Occlusion, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinal Vein Occlusion and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Allergan, Inc. - pSivida Corp. - NicOx S.A. - ThromboGenics NV - Ohr Pharmaceutical Inc. - Kala Pharmaceuticals, Inc. - Mabion SA Drug Profiles - fluocinolone acetonide - squalamine lactate - beclomethasone dipropionate - loteprednol etabonate - ranibizumab - ocriplasmin (recombinant) - NCX-434 - NCX-422 - AVA-101 - ranibizumab biosimilar For more information visit http://www.researchandmarkets.com/research/3b...tinal_vein
Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Clinical Data Presentations at the Retina Society 47th Annual Scientific Meeting
GlobeNewswire - Tue Sep 09, 8:04AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, announced today that data from the IMPACT study, a phase II clinical trial evaluating Squalamine eye drops (OHR-102) for the treatment of the wet form of age-related macular degeneration (wet AMD), will be presented in two separate sessions at the Retina Society 47 Annual Scientific Meeting, being held in Philadelphia, Pennsylvania from September 11-14, 2014.
Ohr Pharmaceutical Announces Additional Squalamine Eye Drop (OHR-102) Phase II Clinical Data in Wet-AMD; The IMPACT Study
GlobeNewswire - Wed Aug 13, 7:30AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced additional interim data from the Phase II study evaluating Squalamine Eye Drops (OHR-102) for the treatment of the wet form of age-related macular degeneration ("wet-AMD"
. The data demonstrated a visual acuity and anatomical benefit for the group of patients receiving the combination of OHR-102 and Lucentis PRN ("OHR-102 arm" versus placebo eye drops plus Lucentis PRN ("Lucentis monotherapy arm" . Jason Slakter, MD, retina specialist and Chief Medical Officer at Ohr, presented the data on Tuesday, August 12 at the 2014 Annual Meeting of the American Society of Retina Specialists ("ASRS" .
Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Phase II Clinical Data in Retinal Vein Occlusion
GlobeNewswire - Mon Aug 11, 8:59AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced data supporting the use of Squalamine Eye Drops (OHR-102) in the treatment of macular edema secondary to branch (BRVO) or central retinal vein occlusion (CRVO). The data demonstrated that the combination of topical Squalamine eye drops and intravitreal Lucentis(R) led to a mean gain in visual acuity ("VA" of 20.3 letters and resolution of the fovial edema in 95% of the patients at week 10. John Wroblewski, MD, retina specialist at Cumberland Valley Retina Consultants, presented the 10 week data on Saturday, August 9 at the 2014 Annual Meeting of the American Society of Retina Specialists.
Ohr Pharmaceutical to Present at the 2014 Wedbush Life Sciences Management Access Conference
GlobeNewswire - Fri Aug 08, 7:04AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Sam Backenroth, Chief Financial Officer, will present a corporate overview and business update at the 2014 Wedbush Life Sciences Management Access Conference, being held at the Le Parker Meridien Hotel in New York City on August 12-13, 2014.
Ohr Pharmaceutical Announces Upcoming Squalamine Eye Drop Clinical Data Presentations at the 2014 Annual Meeting of the American Society of Retina Specialists
GlobeNewswire - Thu Aug 07, 8:32AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that data from clinical studies evaluating Squalamine eye drops for the treatment of macular edema secondary to central and branch retinal vein occlusion, and the wet form of age-related macular degeneration (wet AMD), will be presented in two separate sessions at the 2014 Annual Meeting of the American Society of Retina Specialists, being held at the Hilton Bayfront Hotel in San Diego, California.
Can the Rally in OHR Pharmaceutical (OHRP) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 05, 8:19AM CDT
Can the Rally in OHR Pharmaceutical (OHRP) Shares Continue?
4 Biotech Stocks Under $10 to Trade for Breakouts
at The Street - Fri Aug 01, 6:00AM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.
Anacor Pharmaceuticals, Inc. (ANAC) in Focus: Stock Surges 6.76% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 22, 7:44AM CDT
Anacor Pharmaceuticals, Inc. (ANAC) was a big mover last session, as the company saw its shares surge nearly 7% on the day.
Biotech Stock Mailbag: AcelRx, Yellen Aftermath, Nymox
at The Street - Fri Jul 18, 6:51AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Genocea Biosciences, Inc. (GNCA) in Focus: Stock Rises 7.52% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 17, 7:44AM CDT
Genocea Biosciences, Inc. (GNCA) was a big mover last session, as the company saw its shares rise over 7% on the day.
Strength Seen in La Jolla Pharmaceutical Co. (LJPC): Stock Shoots 19% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 7:44AM CDT
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as the company saw its shares surge 19% on the day.
Aerie Pharmaceuticals, Inc. (AERI) in Focus: Stock up 8.37% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 7:44AM CDT
Aerie Pharmaceuticals, Inc. (AERI) was a big mover last session, as the company saw its shares rise over 8% on the day.
Strength Seen in TherapeuticsMD, Inc. (TXMD): Stock Shoots 32.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 7:44AM CDT
TherapeuticsMD, Inc. (TXMD) was a big mover last session, as the company saw its shares surge over 32% on the day.
Technical Analysis on Health Care Sector Equities -- Research on Ohr Pharma, Synta Pharma, Agenus, and PDL BioPharma
PR Newswire - Wed Jul 09, 5:40AM CDT
The trading session on Tuesday, July 08, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,906.62, down 0.69% and the NASDAQ Composite closed at 4,391.46, down 1.35%. The S&P 500 finished the day 0.70% lower at 1,963.71. The losses were broad based as nine out of ten sectors finished on a negative note. The S&P 500 Health Care Sector Index finished the day at 709.36, down 0.92%, while the index has advanced 2.11% in the previous one month. Investor-Edge has initiated coverage on the following equities: Ohr Pharmaceutical Inc. (NASDAQ: OHRP), Synta Pharmaceuticals Corp. (NASDAQ: SNTA), Agenus Inc. (NASDAQ: AGEN) and PDL BioPharma Inc. (NASDAQ: PDLI). Free technical research on OHRP, SNTA, AGEN and PDLI can be downloaded upon signing up at:
Ohr Pharmaceutical Added to the Russell Indexes
GlobeNewswire - Mon Jun 30, 8:01AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that the Company was added to the Russell Global, Russell 3000, and the Russell Microcap Indexes when Russell Investments reconstituted its comprehensive set of U.S. and global equity indices on June 27, 2014.
Clinical Studies, Trials Results, Appointments, and Technical Updates - Analyst Notes on Ohr, Ariad, Arrowhead, CytRx and Karyopharm Therapeutics
PR Newswire - Fri Jun 27, 4:00AM CDT
Today, Analysts Review released its analysts' notes regarding Ohr Pharmaceutical, Inc. (NASDAQ: OHRP), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Arrowhead Research Corp. (NASDAQ: ARWR), CytRx Corporation (NASDAQ: CYTR) and Karyopharm Therapeutics, Inc. (NASDAQ: KPTI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4203-100free.
Why Ohr Pharmaceuticals (OHRP) Stock Is Soaring Today
at The Street - Thu Jun 26, 3:21PM CDT
Ohr Pharmaceuticals (OHRP) soared Thursday after Vista Partners increased its price target on the stock to $31 from $14.
Vista Partners Updates Coverage on Ohr Pharmaceutical, Inc. (NASDAQ: OHRP); Raises Price Target to $31
Marketwire - Thu Jun 26, 8:02AM CDT
Vista Partners announced today that it has updated coverage on Ohr Pharmaceutical, Inc. (NASDAQ: OHRP) ("The Company" or "OHR" and raised its twelve month price target from $14 to $31. Ross Silver, Principal Analyst at Vista Partners, stated, "OHR is focused on developing Squalamine Eye Drops, currently in a Phase 2 trial, for the treatment of the wet form of age-related macular degeneration (Wet-AMD), a chronic eye disease that causes vision loss in the center of your field of vision. Therapies for Wet-AMD such as ranibizumab (Lucentis(R)) sold by Genentech (acquired by Roche), as well as Regeneron's aflibercept (Eylea(R)) intravitreal injections, have become the market leaders in treating Wet-AMD and both therapies combined garnered approximately $6B of revenues in 2013. OHR's Wet-AMD clinical candidate Squalamine eye drops showed gains in visual acuity according to the interim data presented Tuesday this week. The current forms of approved treatment, Lucentis(R) and Eylea(R), require an injection into the back of the eye. Also in clinical development, Opthotech's Fovista(R), requires an injection into the back of the eye post an initial Lucentis(R) injection and is being developed to increase visual acuity. Squalamine Eye Drops would seem to present a significant advantage relative to the aforementioned therapy (Fovista(R)) considering Squalamine Eye Drops delivery method which is self-administered eye drops. Squalamine Eye Drops may have the potential to create a monumental shift in the way patients are treated for Wet-AMD if approved. The positive visual acuity results also provide a possible trajectory for a Phase 3 trial design." Mr. Silver concludes, "OHR completed an equity financing of $18M in April 2014, which according to the Company, gives them a cash runway well into 2016."
Ohr Pharma Applies a Ton of Lipstick to Squalamine Pig
at The Street - Tue Jun 24, 11:07AM CDT
A phase II study of Squalamine in wet age-related macular degeneration bombed badly.
Retinal Vein Occlusion - Pipeline Review, H2 2014 - 8 Companies & 10 Drug Profiles
M2 - 1 hr 42 mins ago
Research and Markets (http://www.researchandmarkets.com/research/3bmznr/retinal_vein) has announced the addition of the "Retinal Vein Occlusion - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Retinal Vein Occlusion, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinal Vein Occlusion and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Allergan, Inc. - pSivida Corp. - NicOx S.A. - ThromboGenics NV - Ohr Pharmaceutical Inc. - Kala Pharmaceuticals, Inc. - Mabion SA Drug Profiles - fluocinolone acetonide - squalamine lactate - beclomethasone dipropionate - loteprednol etabonate - ranibizumab - ocriplasmin (recombinant) - NCX-434 - NCX-422 - AVA-101 - ranibizumab biosimilar For more information visit http://www.researchandmarkets.com/research/3b...tinal_vein
Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Clinical Data Presentations at the Retina Society 47th Annual Scientific Meeting
GlobeNewswire - Tue Sep 09, 8:04AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, announced today that data from the IMPACT study, a phase II clinical trial evaluating Squalamine eye drops (OHR-102) for the treatment of the wet form of age-related macular degeneration (wet AMD), will be presented in two separate sessions at the Retina Society 47 Annual Scientific Meeting, being held in Philadelphia, Pennsylvania from September 11-14, 2014.
Ohr Pharmaceutical Announces Additional Squalamine Eye Drop (OHR-102) Phase II Clinical Data in Wet-AMD; The IMPACT Study
GlobeNewswire - Wed Aug 13, 7:30AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced additional interim data from the Phase II study evaluating Squalamine Eye Drops (OHR-102) for the treatment of the wet form of age-related macular degeneration ("wet-AMD"
. The data demonstrated a visual acuity and anatomical benefit for the group of patients receiving the combination of OHR-102 and Lucentis PRN ("OHR-102 arm" versus placebo eye drops plus Lucentis PRN ("Lucentis monotherapy arm" . Jason Slakter, MD, retina specialist and Chief Medical Officer at Ohr, presented the data on Tuesday, August 12 at the 2014 Annual Meeting of the American Society of Retina Specialists ("ASRS" . Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Phase II Clinical Data in Retinal Vein Occlusion
GlobeNewswire - Mon Aug 11, 8:59AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced data supporting the use of Squalamine Eye Drops (OHR-102) in the treatment of macular edema secondary to branch (BRVO) or central retinal vein occlusion (CRVO). The data demonstrated that the combination of topical Squalamine eye drops and intravitreal Lucentis(R) led to a mean gain in visual acuity ("VA"
of 20.3 letters and resolution of the fovial edema in 95% of the patients at week 10. John Wroblewski, MD, retina specialist at Cumberland Valley Retina Consultants, presented the 10 week data on Saturday, August 9 at the 2014 Annual Meeting of the American Society of Retina Specialists. Ohr Pharmaceutical to Present at the 2014 Wedbush Life Sciences Management Access Conference
GlobeNewswire - Fri Aug 08, 7:04AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Sam Backenroth, Chief Financial Officer, will present a corporate overview and business update at the 2014 Wedbush Life Sciences Management Access Conference, being held at the Le Parker Meridien Hotel in New York City on August 12-13, 2014.
Ohr Pharmaceutical Announces Upcoming Squalamine Eye Drop Clinical Data Presentations at the 2014 Annual Meeting of the American Society of Retina Specialists
GlobeNewswire - Thu Aug 07, 8:32AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that data from clinical studies evaluating Squalamine eye drops for the treatment of macular edema secondary to central and branch retinal vein occlusion, and the wet form of age-related macular degeneration (wet AMD), will be presented in two separate sessions at the 2014 Annual Meeting of the American Society of Retina Specialists, being held at the Hilton Bayfront Hotel in San Diego, California.
Can the Rally in OHR Pharmaceutical (OHRP) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 05, 8:19AM CDT
Can the Rally in OHR Pharmaceutical (OHRP) Shares Continue?
4 Biotech Stocks Under $10 to Trade for Breakouts
at The Street - Fri Aug 01, 6:00AM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.
Anacor Pharmaceuticals, Inc. (ANAC) in Focus: Stock Surges 6.76% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 22, 7:44AM CDT
Anacor Pharmaceuticals, Inc. (ANAC) was a big mover last session, as the company saw its shares surge nearly 7% on the day.
Biotech Stock Mailbag: AcelRx, Yellen Aftermath, Nymox
at The Street - Fri Jul 18, 6:51AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Genocea Biosciences, Inc. (GNCA) in Focus: Stock Rises 7.52% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 17, 7:44AM CDT
Genocea Biosciences, Inc. (GNCA) was a big mover last session, as the company saw its shares rise over 7% on the day.
Strength Seen in La Jolla Pharmaceutical Co. (LJPC): Stock Shoots 19% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 7:44AM CDT
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as the company saw its shares surge 19% on the day.
Aerie Pharmaceuticals, Inc. (AERI) in Focus: Stock up 8.37% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 7:44AM CDT
Aerie Pharmaceuticals, Inc. (AERI) was a big mover last session, as the company saw its shares rise over 8% on the day.
Strength Seen in TherapeuticsMD, Inc. (TXMD): Stock Shoots 32.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 7:44AM CDT
TherapeuticsMD, Inc. (TXMD) was a big mover last session, as the company saw its shares surge over 32% on the day.
Technical Analysis on Health Care Sector Equities -- Research on Ohr Pharma, Synta Pharma, Agenus, and PDL BioPharma
PR Newswire - Wed Jul 09, 5:40AM CDT
The trading session on Tuesday, July 08, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,906.62, down 0.69% and the NASDAQ Composite closed at 4,391.46, down 1.35%. The S&P 500 finished the day 0.70% lower at 1,963.71. The losses were broad based as nine out of ten sectors finished on a negative note. The S&P 500 Health Care Sector Index finished the day at 709.36, down 0.92%, while the index has advanced 2.11% in the previous one month. Investor-Edge has initiated coverage on the following equities: Ohr Pharmaceutical Inc. (NASDAQ: OHRP), Synta Pharmaceuticals Corp. (NASDAQ: SNTA), Agenus Inc. (NASDAQ: AGEN) and PDL BioPharma Inc. (NASDAQ: PDLI). Free technical research on OHRP, SNTA, AGEN and PDLI can be downloaded upon signing up at:
Ohr Pharmaceutical Added to the Russell Indexes
GlobeNewswire - Mon Jun 30, 8:01AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that the Company was added to the Russell Global, Russell 3000, and the Russell Microcap Indexes when Russell Investments reconstituted its comprehensive set of U.S. and global equity indices on June 27, 2014.
Clinical Studies, Trials Results, Appointments, and Technical Updates - Analyst Notes on Ohr, Ariad, Arrowhead, CytRx and Karyopharm Therapeutics
PR Newswire - Fri Jun 27, 4:00AM CDT
Today, Analysts Review released its analysts' notes regarding Ohr Pharmaceutical, Inc. (NASDAQ: OHRP), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Arrowhead Research Corp. (NASDAQ: ARWR), CytRx Corporation (NASDAQ: CYTR) and Karyopharm Therapeutics, Inc. (NASDAQ: KPTI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4203-100free.
Why Ohr Pharmaceuticals (OHRP) Stock Is Soaring Today
at The Street - Thu Jun 26, 3:21PM CDT
Ohr Pharmaceuticals (OHRP) soared Thursday after Vista Partners increased its price target on the stock to $31 from $14.
Vista Partners Updates Coverage on Ohr Pharmaceutical, Inc. (NASDAQ: OHRP); Raises Price Target to $31
Marketwire - Thu Jun 26, 8:02AM CDT
Vista Partners announced today that it has updated coverage on Ohr Pharmaceutical, Inc. (NASDAQ: OHRP) ("The Company" or "OHR"
and raised its twelve month price target from $14 to $31. Ross Silver, Principal Analyst at Vista Partners, stated, "OHR is focused on developing Squalamine Eye Drops, currently in a Phase 2 trial, for the treatment of the wet form of age-related macular degeneration (Wet-AMD), a chronic eye disease that causes vision loss in the center of your field of vision. Therapies for Wet-AMD such as ranibizumab (Lucentis(R)) sold by Genentech (acquired by Roche), as well as Regeneron's aflibercept (Eylea(R)) intravitreal injections, have become the market leaders in treating Wet-AMD and both therapies combined garnered approximately $6B of revenues in 2013. OHR's Wet-AMD clinical candidate Squalamine eye drops showed gains in visual acuity according to the interim data presented Tuesday this week. The current forms of approved treatment, Lucentis(R) and Eylea(R), require an injection into the back of the eye. Also in clinical development, Opthotech's Fovista(R), requires an injection into the back of the eye post an initial Lucentis(R) injection and is being developed to increase visual acuity. Squalamine Eye Drops would seem to present a significant advantage relative to the aforementioned therapy (Fovista(R)) considering Squalamine Eye Drops delivery method which is self-administered eye drops. Squalamine Eye Drops may have the potential to create a monumental shift in the way patients are treated for Wet-AMD if approved. The positive visual acuity results also provide a possible trajectory for a Phase 3 trial design." Mr. Silver concludes, "OHR completed an equity financing of $18M in April 2014, which according to the Company, gives them a cash runway well into 2016." Ohr Pharma Applies a Ton of Lipstick to Squalamine Pig
at The Street - Tue Jun 24, 11:07AM CDT
A phase II study of Squalamine in wet age-related macular degeneration bombed badly.
